CASE REPORT
Soft tissue metastasis of mediastinal non-functioning paraganglioma with unusual TTF-1 expression: a potential diagnostic pitfall
 
More details
Hide details
 
Submission date: 2017-05-25
 
 
Acceptance date: 2017-07-10
 
 
Publication date: 2018-03-06
 
 
Pol J Pathol 2017;68(4):354-358
 
KEYWORDS
TOPICS
ABSTRACT
Metastatic extra-adrenal paragangliomas are very rare and can represent diagnostic challenges. We report a case of 69-year-old man with a tumor of the right shoulder. Histologic and immunohistochemical examinations confirmed the diagnosis of paraganglioma. Surprisingly, tumor cells were diffusely thyroid transcription factor 1 (TTF-1) positive. Succinate dehydrogenase complex subunit B (SDHB) deficiency has not been detected. Inherited syndromes associated with paragangliomas were ruled out. The primary tumor was identified in the mediastinum. This is the first report of TTF-1 expression in paraganglioma. To avoid misdiagnosis, careful clinical and pathological examination of any tumor with organoid growths pattern is necessary.
REFERENCES (26)
1.
DeLellis RA, Lloyd RV, Heitz PU, Eng C. Tumours of the adrenal gland. In: Pathology and Genetics of Tumours of the Endocrine Organs. WHO Classification of Tumours. 3rd ed. IARC press, Lyon 2004; 159-166.
 
2.
Welander J, Söderkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer 2011; 18: R253.
 
3.
Lee JA, Duh QY. Sporadic paraganglioma. World J Surg 2008; 32: 683-687.
 
4.
O’Riordain DS, William F, Young J, et al. Clinical Spectrum and Outcome of Functional Extraadrenal Paraganglioma. World J Surg 1996; 20: 916-922.
 
5.
Ayala-Ramirez M, Feng L, Johnson MM, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: Primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 2011; 96: 717-725.
 
6.
Khan Q, Heath D, Smith P, Norboo T. The histology of the carotid bodies in highlanders from Ladakh. Int J Bioeteorol 1988; 32: 254.
 
7.
Rodríguez-Cuevas S, López-Garza J, Lbastida-Almendaro S. Carotid body tumors in inhabitans of altitudes higher than 2000 meters above sea level. Head Neck 1998; 20: 374.
 
8.
Dannenberg H, Dinjens WN, Abbou M, et al. Frequent germ-line succinate dehydrogenase subunit D gene mutations in patients with apparently sporadic parasympathetic paraganglioma. Clin Cancer Res 2002; 8: 2061-2066.
 
9.
Brown ML, Zayas GE, Abel MD, et al. Mediastinal paragangliomas: the Mayo Clinic experience. Ann Thorac Surg 2008; 86: 946-951.
 
10.
Ma L, Mei J, Liu L. Thoracoscopic resection of functional posterior mediastinal paraganglioma: case report. J Thorac Dis 2014; 6: 1861-1864.
 
11.
Milka M, Braham E, Hamrouni R, Zribi H. About a challenging mediastinal tumor. Asian Cardiovasc Thorac Ann 2015; 23: 1125-1128.
 
12.
Suster S, Moran C. Neuroendocrine tumors of the mediastinum. Am J Clin Pathol 2001; 115(suppl 1): S17-27.
 
13.
Wald O, Shapira OM, Murar A, Izhar U: Paraganglioma of the mediastinum: challenges in diagnosis and surgical management. J Cardiothorac Surg 2010; 5: 19.
 
14.
González-Santos JM, Arnáiz-Garciá ME, Mu¼oz-Herrera Á, López-Rodríguez J: Mediastinal paraganglioma fed by the left circumflex artery. Interact Cardiovasc Thorac Surg 2016; 23: 835-836.
 
15.
Lamy AL, Fradet GJ, Luoma A, Nelems B. Anterior and middle mediastinum paraganglioma: complete resection is the treatment of choice. The Annals of Thoracic Surgery 1994; 57: 249-252.
 
16.
Tanabe A, Naruse M, Nomura K, et al. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm Cancer 2013; 4: 103-110.
 
17.
Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2004; 24: 401-406.
 
18.
Ayala-Ramirez M, Feng L, Habra MA, et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 2012; 118: 2804-2812.
 
19.
Ayala-Ramirez M, Chougnet CN, Habra MA, et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. The J Clin Endocrinol Metab 2012; 97: 4040-4050.
 
20.
Pacak K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 2007; 3: 92-102.
 
21.
Feng N, Zhang WY, Wu XT. Clinicopathological analysis of paraganglioma with literature review. World J Gastroenterol 2009; 15: 3003-3009.
 
22.
van Nederveen FH, Gaal J, Favier J, Korpershoek E, et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 2009; 10: 764-771.
 
23.
Brouwers FM, Eisenhofer G, Tao JJ, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinom Metab 2006; 91: 4505-4509.
 
24.
Häyry V, Salmenkivi K, Arola J, et al. High frequency of SNAIL-expressing cells confirms and predicts metastatic potential of phaeochromocytoma. Endocr Relat Cancer 2009; 16: 1211-1218.
 
25.
Abdullah AE, Guerin C, Imperiale A, et al. Paraganglioma of the organ of Zuckerkandl associated with a somatic HIF2α mutation: a case report. Oncology Letters 2017; 13: 1083-1086.
 
26.
Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 2003; 63: 5615-5621.
 
eISSN:2084-9869
ISSN:1233-9687
Journals System - logo
Scroll to top